NASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis $0.58 -0.02 (-3.92%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Citius Pharmaceuticals Stock (NASDAQ:CTXR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Citius Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.57▼$0.6050-Day Range$0.48▼$0.7852-Week Range$0.47▼$2.19Volume154,929 shsAverage Volume359,276 shsMarket Capitalization$15.82 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for underserved areas of healthcare. The company has historically concentrated on anti-infective therapies, oncology treatments and supportive-care products, with an emphasis on therapies that address significant unmet medical needs. Citius’ lead programs have included Mino-Lok, an investigational antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while preserving the catheter. The company has also developed LYMPHIR (denileukin diftitox-cxdl), an oncology therapy for adults with relapsed or refractory cutaneous T-cell lymphoma. LYMPHIR received approval from the U.S. Food and Drug Administration in 2024 and is being advanced through the company’s oncology operations. The company’s activities have primarily focused on the U.S. market and on obtaining regulatory approval and commercializing specialty therapies. Citius Pharmaceuticals was founded in 2010 and is headquartered in New Jersey. Its leadership has included Myron Holubiak as chief executive officer and Leonard Mazur as chairman, although management roles may change over time.AI Generated. May Contain Errors. Read More Citius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCTXR MarketRank™: Citius Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 672nd out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingCitius Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCitius Pharmaceuticals has a consensus price target of $5.00, representing about 767.3% upside from its current price of $0.58.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Citius Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Pharmaceuticals is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Pharmaceuticals is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.59% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 6.06.Change versus previous monthShort interest in Citius Pharmaceuticals has recently increased by 4.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Citius Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 6 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders4.99% of the stock of Citius Pharmaceuticals is held by insiders.Percentage Held by Institutions16.88% of the stock of Citius Pharmaceuticals is held by institutions.Read more about Citius Pharmaceuticals' insider trading history. Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTXR Stock News HeadlinesTarsus Pharmaceuticals (NASDAQ:TARS) and Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head ComparisonSeptember 21 at 2:15 AM | americanbankingnews.comCitius Pharmaceuticals Highlights LYMPHIR Launch Momentum, Expanding CTCL ReachSeptember 20 at 3:02 AM | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Average Rating of "Hold" from BrokeragesSeptember 13, 2026 | americanbankingnews.comCitius Pharmaceuticals to Participate in September 2026 Investor ConferencesSeptember 3, 2026 | prnewswire.comCitius Pharmaceuticals Receives Nasdaq Extension to Regain ComplianceAugust 22, 2026 | theglobeandmail.comCitius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | prnewswire.comSee More Headlines CTXR Stock Analysis - Frequently Asked Questions How have CTXR shares performed this year? Citius Pharmaceuticals' stock was trading at $0.7770 at the beginning of 2026. Since then, CTXR stock has decreased by 25.8% and is now trading at $0.5765. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split on the morning of Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Citius Pharmaceuticals' major shareholders? Citius Pharmaceuticals' top institutional shareholders include BlackRock Inc. (0.25%). View institutional ownership trends. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/14/2026Today9/21/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CTXR's financial health is in the Red zone, according to TradeSmith. CTXR has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CTXR CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees20Year Founded2007Price Target and Rating Average Price Target for Citius Pharmaceuticals$5.00 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+767.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.43 million Net MarginsN/A Pretax Margin-816.00% Return on Equity-59.57% Return on Assets-34.47% Debt Debt-to-Equity Ratio0.08 Current Ratio0.84 Quick Ratio0.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.13Miscellaneous Outstanding Shares27,450,000Free Float26,083,000Market Cap$15.82 million OptionableOptionable Beta1.00 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CTXR) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...Trading Wire | SponsoredA Scary Development Every AI Investor Needs to Take Note OfMicron surged over 500% in the past year, Intel climbed more than 250%, and AMD soared over 250% - but a $194 ...Weiss Ratings | SponsoredElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and M...Porter & Company | SponsoredIran War: Someone Just Demanded Trump Ride To The RescueA powerful Middle East government has publicly asked President Trump for U.S. military help against Iran-backe...Banyan Hill Publishing | SponsoredTicker confettiEndless tickers, endless tabs, endless noise. Jeff Z.'s Monthly Money Flows narrows it down to one new trade i...Millionaire Pub | SponsoredADD TO CALENDAR: September 25thA newly uncovered FCC filing reveals what could be Elon Musk's next major project, one some believe could riva...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
